We investigated whether the combination of chlormadinone acetate (CMA) and a luteinizing hormone releasing hormone (LH-RH) agonist, leuprorelin acetate (leuprorelin), more markedly decreased ventral prostate and seminal vesicle weights and plasma sex hormone levels in male rats. Four weeks after administration of 0.28, 0.84 or 2.8 mg/kg of leuprorelin, ventral prostate weights significantly decreased (53.8, 54.4 and 64.1%) and the plasma testosterone levels significantly lowered, but not dose-dependently. After repetitive administrations of 3 and 30 mg/kg/day of CMA, the rates of ventral prostatic atrophy were 37.1 and 65.9%, respectively. Although there was no change in the plasma testosterone level at 3 mg/kg, 30 mg/kg of CMA significantly decreased the level. A combination of leuprorelin (0.28 mg/kg) and CMA (3 or 30 mg/kg) more potently induced ventral prostatic and seminal vesicle atrophy than leuprorelin alone. Furthermore, a combination of leuprorelin and CMA (30 mg/kg) more markedly decreased the plasma testosterone level. According to the pharmacokinetic data for CMA in male rats, the doses of CMA correspond to the clinical dose. These findings suggest that combination therapy with an LH-RH agonist and CMA is more useful than therapy with the agonist alone in the treatment of prostate cancer.
Introduction
Endocrine therapy is the most frequently employed treatment for prostate cancer, and luteinizing hormone releasing hormone (LH-RH) agonists alone or in combination with anti-androgen agents are commonly prescribed. 1 -7 This combination is sometimes referred to as combined androgen blockade (CAB) therapy.
Chlormadinone acetate (CMA) is one of the steroidal anti-androgen agents used in CAB therapy as well as monotherapy for prostate cancer in Japan. 4, 8 Steroidal anti-androgen agents have been known to possess both actions of antagonizing androgen to bind its receptor and lowering the plasma androgen levels. Moreover, CMA reduces the secretion of androgen not only from the gonads but also from the adrenal. A recent study has reported that CAB therapy with CMA and an LH-RH agonist achieved better clinical results than LH-RH agonist monotherapy for prostate cancer. 4 However, it is still unknown whether the better clinical result with CMA is due to the action of reducing the secretion of androgen from the gonads or adrenal.
In this study, we examined whether the combination of an LH-RH agonist and CMA more potently decreased accessory genital organ weights as well as plasma hormone levels. We also investigated whether the abovementioned clinical results were supported at the basic experimental level. To avoid interference by adrenal androgen, we used male rats in which the secretion of testosterone occurs exclusively in the testis.
Methods Animals
Eleven-week-old male Sprague -Dawley rats (Charles River Japan) were used. All experiments were conducted in accordance with the Guideline for Animal Experiments (Japanese Association for Laboratory Animal Science, 1987).
As a negative and a positive control, a vehicle-treated group and a castration group were established, respectively. The number of animals per group was eight. Body weight was measured the day before the initial administration. Grouping was conducted so that there was no difference in mean body weight. In the castration group, bilateral orchiectomy was performed under anesthesia with ketamine (50 -80 mg/kg i.p.). Four weeks after the first administration of drugs to be tested, blood was collected under ether anesthesia after body weight was measured. Blood samples were used to measure the plasma testosterone levels. Then, the ventral prostate and seminal vesicle were extirpated, and wet weights were measured.
Drugs
As an LH-RH agonist, a leuprorelin acetate (leuprorelin) microcapsule sustained-release preparation (Leuplin 1 ) was used. CMA was synthesized at Teikoku Hormone Mfg Co. Ltd.
Leuprorelin was suspended in the accompanying suspension to prepare a concentration of 1.875 mg/ml. CMA was suspended in 2% Tween 80/physiological saline to prepare concentrations of 0.6 and 6 mg/ml.
Dose-dependency of leuprorelin and CMA
We investigated doses of 0.28, 0.84 and 2.8 mg/kg of leuprorelin, which was subcutaneously administered once to the back of rats. We also investigated doses of 3 and 30 mg/kg of CMA. Three or 30 mg/kg of CMA was subcutaneously administered to the back once a day for 4 weeks. Six hours after the final administration, rats were sacrificed.
Combination with leuprorelin and CMA
We compared the effects of 0.28 mg/kg of leuprorelin alone with a combination of leuprorelin and either 3 or 30 mg/kg of CMA. Six hours after the final administration of CMA, rats were sacrificed. Blood samples were used to measure not only the plasma testosterone level but also the levels of two gonadotropins (luteinizing hormone (LH) and follicle stimulating hormone (FSH)).
Measurement of plasma testosterone, LH, FSH and CMA levels
Plasma samples were isolated from the whole blood samples obtained. Plasma testosterone levels were measured by liquid chromatography -tandem mass spectrometry (LC-MS/MS), 9 because LC-MS/MS is more precise and reliable than the conventional radioimmunoassay (RIA) method. Plasma LH and FSH levels were measured by RIA. The lower detection limits of plasma testosterone, LH and FSH were 0.05, 0.8 and 1.6 ng/ml, respectively. { P < 0.05, vs vehicle-control (Dunnett's test).
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To evaluate whether the doses of CMA investigated in this study were appropriate, 3 mg/kg of CMA was subcutaneously administered once, and plasma CMA levels were measured. At 1, 2, 3, 6, 8 and 24 h after CMA administration, blood was collected under ether anesthesia. At each time point, plasma CMA levels were measured by gas chromatography -mass spectrometry (GC/MS) in three animals. The lower detection limit of plasma CMA was 0.2 ng/ml.
Data analysis
Data are expressed as the mean AE s.d. or mean alone. Wet organ weights are expressed as corrected values (mg/100 g body weight). When each plasma concentration was below the lower detection limit, the value was taken as one-half of the individual limit.
Significance was tested as follows: when values were compared between two groups, the two-sample t-test was used. When values were compared among three or more groups, one-sided Dunnett's test was used (SAS system Release 6.12). P < 0.05 was regarded as significant.
Results

Dose-dependency of leuprorelin
In comparison to the vehicle-treated group, the rates of atrophy of prostate and seminal vesicle in the castration group were 91.4 and 76.5%, respectively ( Figure 1) . The plasma testosterone level in the castration group was less than the lower detection limit, 0.05 ng/ml ( Figure 2 ).
After administration of 0.28, 0.84 and 2.8 mg/kg of leuprorelin, ventral prostate weights and seminal vesicle weights were reduced significantly ( Figure 1 ). In comparison to the vehicle-treated group, the rates of prostatic atrophy were 53.8, 54.4 and 64.1% in the three dose groups, respectively. The rates of seminal vesicle atrophy were 55.3, 57.4 and 61.1%, respectively. After the three doses of leuprorelin, the plasma testosterone levels were reduced significantly ( Figure 2 ).
There was no significant difference among the three dose groups in these leuprorelin-related actions. In addition, even at the highest dose (2.8 mg/kg) tested in this study, these leuprorelin-related effects were less marked than the castration-related effects. Figure 2 Effects of leuprorelin acetate on plasma testosterone concentration in rats. Data were obtained 4 weeks after the administration. Each column represents the mean AE s.d. of eight rats. *P < 0.05, vs vehicle-control (two-sample t-test). Figure 3) . In comparison to vehicle-treated group, the rates of prostatic atrophy were 37.1 and 65.9%, respectively. The rates of seminal vesicle atrophy were 27.9 and 71.5%, respectively. The plasma testosterone level in the 30 mg/kg group was significantly lower than the vehicle-treated group. However, there was no significant change in the 3 mg/kg group (Figure 4 ).
Combination with leuprorelin and CMA
The rates of prostatic atrophy by the combination of 3 or 30 mg/kg of CMA with 0.28 mg/kg of leuprorelin, compared with the vehicle-treated group, were 60.0 and 69.3%, respectively. These effects were significantly more potent than that of the rats given 0.28 mg/kg of leuprorelin alone (37.7%). The similar results were obtained in the seminal vesicle weights ( Figure 5 ). A combination of 30 mg/kg of CMA with leuprorelin decreased the plasma testosterone level to 0.08 AE 0.06 ng/ml. This value was significantly lower than that in the group treated with leuprorelin alone (0.44 AE 0.30 ng/ml). On the other hand, the testosterone-lowering effects of leuprorelin were not influenced by a combination with 3 mg/kg of CMA ( Figure 6) .
Administration of 0.28 mg/kg of leuprorelin alone significantly decreased the plasma FSH level. This effect was significantly potentiated when leuprorelin was combined with 3 or 30 mg/kg of CMA ( Figure 6 ). However, FSH levels in rats seem to decrease less than those in humans. There was no change in plasma LH levels in any groups (data not shown). Generally, it has been reported that plasma LH-lowering effects do not normally appear in rats, dissimilarly form humans. Moreover, plasma LH levels in rats may be less sensitive to change than FSH.
Plasma CMA level after a single dose of CMA The maximal CMA concentration (C max 25.8 ng/ml) was obtained 1 h after the administration. The area under the Figure 4 Effects of chlormadinone acetate (CMA) on plasma testosterone concentration in rats. Each column represents the mean AE s.d. of eight rats. *P < 0.05, vs vehicle-control (two-sample t-test). 
Discussion
Currently, LH-RH agonists are mainly prescribed for endocrine therapy for prostate cancer, and CAB therapy with LH-RH agonists and anti-androgen agents has commonly been administered to improve clinical results. 1 -7 CAB therapy aims at not only eliminating testis-derived testosterone by LH-RH agonists but also blocking the action of adrenal androgen by anti-androgen agents, since it is thought that adrenal androgens are also important to the active androgen, dihydrotestosterone, in the prostate in men, 10, 11 unlike in rats where the secretion of androgens occurs exclusively in the gonads. However, LH-RH agonists may be unable to sufficiently lower plasma testosterone levels, according to the report by Oefelein and colleagues. 12 They have reported that the plasma testosterone level was still higher than a tentative castration level of 0.5 ng/ml in 5% of patients with prostate cancer treated with an LH-RH agonist monotherapy, and such percentage of patients increased to 13% if the tentative castration level was 0.2 ng/ml. 12 Among anti-androgen agents, steroidal compounds can lower the plasma testosterone level by a central negative feedback mechanism and antagonize androgen to bind its receptor. In Japan, CMA, one of the steroidal anti-androgen agents, had been the only available anti-androgen agent for prostate cancer until a non-steroidal anti-androgen agent, flutamide, was launched. Moreover, CMA has been known to reduce the secretion of adrenal androgen by inhibiting the secretion of adrenocorticotropic hormone from the pituitary, as well as the secretion of gonadal androgen. A recent clinical study has reported that combination therapy with CMA and an LH-RH agonist showed better long-term results than the LH-RH agonist monotherapy. 4 These better long-term results are probably due to the synergistic effect of CMA on the plasma testosteronelowering effect of the LH-RH agonist. Therefore, we investigated whether CMA potentiated the plasma testosterone-lowering effect of the LH-RH agonists in rats, and whether the above-mentioned clinical results and the hypothesis about the mechanism of better clinical results were supported at the basic experimental level.
We used leuprorelin as an LH-RH agonist in this study. The clinical dose of leuprorelin in the treatment of prostate cancer is 3.75 mg at 4 week intervals, in Asia including Japan and in Europe. Based on body surface area in Synergistic effect of CMA and LH-RH agonist K Gotanda et al humans weighing 60 kg (1.62 m 2 ) and rats weighing 100 g (0.017 m 2 ), the dose of 3.75 mg was calculated into approximately 0.4 mg/kg at 4 week intervals as the corresponding dose for rats. In this study, we investigated the dose-dependency of leuprorelin within a range including the calculated dose, that is, at 0.28, 0.84 and 2.8 mg/kg. Four weeks after a single-dose subcutaneous administration of leuprorelin, prostate weight and the plasma testosterone levels in rats decreased significantly, even at the minimal dose investigated (0.28 mg/kg). However, the actions of leuprorelin at higher doses were not enhanced, and did not reach the level in castrated rats. This result is consistent with results reported previously, investigating the dose-dependency of leuprorelin. 13 Repetitive subcutaneous daily administration of 3 and 30 mg/kg of CMA for 4 weeks decreased dose-dependently prostate and seminal vesicle weights in rats. Dissimilarly to accessory genital organ weights, 3 mg/kg of CMA did not influence the plasma testosterone levels, although 30 mg/kg of CMA markedly decreased those levels. At the two doses of CMA investigated in this study, the rates of prostatic atrophy were near to 50%, and the dose ranges included the threshold of the testosteronelowering effect. These doses exhibit moderate effects and may not be excessive. To examine the relation between the doses administered to rats and the clinical dose, furthermore, we measured plasma CMA levels in rats after the administration of 3 mg/kg of CMA. As a result, the AUC 0 -24hr for the plasma CMA level was approximately 225 ng h/ml. In humans, it was reported that the AUC 0 -24hr for the plasma CMA level was approximately 200 ng h/ml after oral administration of a 25 mg tablet. 14 Therefore, the AUC 0 -24hr after administration of 3 and 30 mg/kg of CMA to rats may be onethird and 3-fold of the AUC 0 -24hr in humans after oral administration of 100 mg, clinical dose for prostate cancer. Although this estimation should be verified further, doses of 3 and 30 mg/kg of CMA to rats may correspond to the clinical dose for prostate cancer.
Based on the results regarding the dose-dependency of leuprorelin and CMA, and pharmacokinetic profile of CMA, we investigated and effects of combination of 0.28 mg/kg of leuprorelin with 3 or 30 mg/kg of CMA in rats. Similarly to the effects after administration of CMA alone, 3 mg/kg of CMA with leuprorelin did not influence the plasma testosterone-lowering effect, but potentiated the prostatic and seminal vesicle atrophy by leuprorelin alone. On the other hand, the higher dose of CMA, 30 mg/kg, potentiated both effects of leuprorelin on the plasma testosterone levels and the accessory genital organ weights. Thus, there was a dissociation in the dose producing CMA-related prostatic atrophy and plasma testosterone-lowering effects, regardless of the presence or absence of leuprorelin. This result suggests that CMA mainly induces prostatic atrophy via direct anti-androgen action at 3 mg/kg, while CMA more potently induces prostatic atrophy via both direct anti-androgen action and the plasma testosterone-lowering effect at 30 mg/kg. CMA may exhibit the ability to reduce prostatic size of patients with prostate cancer and benign prostatic hypertrophy via the plasma testosterone-lowering effect in addition to direct anti-androgen activity which is essential for the counterpart of an LH-RH agonist in CAB therapy.
The effect obtained by combination with 0.28 mg/kg of leuprorelin and 30 mg/kg of CMA was more potent than that by the dose escalating up to 10-fold (2.8 mg/kg) in leuprorelin monotreatment. This result suggests that the mechanism of action differs between leuprorelin and CMA. The mechanism of LH-RH agonists to lower plasma testosterone levels is thought to down-regulate LH-RH receptors in the pituitary. Dissimilarly, a negative feedback mechanism in the hypothalamus and pituitary seems to be involved in the plasma testosterone-lowering effect of the steroidal anti-androgen agents, including CMA. With regard to the negative feedback mechanism in the hypothalamus, Skinner et al reported that progesterone powerfully inhibits the secretion of LH-RH from the hypothalamus via a negative feedback mechanism at its own receptor in the hypothalamus. 15 In this respect, CMA also probably inhibits LH-RH secretion from the hypothalamus, since CMA possesses progesterone mimetic action. Thus, it is suggested that CMA exhibits negative feedback action in the hypothalamus as well as in the pituitary and that such action is reflected in the results in the present study with rats and the better longterm results by CAB therapy using CMA in clinical. This feature is not shared by non-steroidal anti-androgen agents, flutamide, bicalutamide, etc, and may be a major advantage in CAB therapy with LH-RH agonists.
Furthermore, agents lowering the plasma testosterone levels may also be useful for preventing a worsening of symptoms caused by transient increases in testosterone, that is, flare-up, after the initial administration of LH-RH agonists. In clinical practice, it has been reported that CMA administered prior to leuprorelin inhibited a transient increase in the secretion of LH in patients with prostate cancer in comparison with patients not given CMA, 16 and that CAB therapy with CMA was found effective in inhibiting flare-up related to LH-RH agonists. 17, 18 
Conclusion
The steroidal anti-androgen agent, CMA, may have the advantage of lowering the plasma testosterone level via central negative feedback mechanisms. The results of this simple experiment using rats may show one of the mechanisms by which combination therapy with an LH-RH agonist and CMA achieves better clinical results than treatment with the agonist alone. CMA may be a useful anti-androgen agent in CAB therapy.
